Skip to content

Investigating the SMA's Role in Speech and Reading Fluency in PWS With rTMS

Investigating the Supplementary Motor Area Role in Speech and Reading Fluency in PWS With rTMS

Status
Enrolling by invitation
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06809387
Enrollment
15
Registered
2025-02-05
Start date
2025-01-01
Completion date
2025-06-15
Last updated
2025-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stuttering, Adult

Keywords

rTMS, stuttering, SMA

Brief summary

The goal of this clinical trial is to study how a part of the brain called the supplementary motor area (SMA) is connected to speech and reading fluency in adults who stutter. Researchers will use a method called repetitive transcranial magnetic stimulation (rTMS) to learn more about this relationship. The main question it aims to answer is: -Will participants' speech and reading fluency improve when we stimulate the SMA with rTMS? Participants will take part in both placebo rTMS and real rTMS sessions. Participants will: * Come to the research center for 2 days, with at least a one-week break between visits * Read 4 passages and speak on 4 topics * Be video recorded while doing these tasks

Interventions

OTHERBrain stimulation

Participants will be included in the real and sham rTMS. Participants will perform speech and reading tasks before and after stimulation.

Sponsors

Medipol University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* To be over 18 years of age * Presence of developmental stuttering * Being right hand dominant

Exclusion criteria

* Being under 18 years of age * The presence of a diagnosed brain lesion * Presence of intracranial metal implantation * Presence of a speech and language problem other than stuttering * The presence of a diagnosed neurological disorder * The presence of a diagnosed psychiatric disorder * Use of drugs and substances that may affect the central nervous system * History of epilepsy

Design outcomes

Primary

MeasureTime frameDescription
Severity of stuttering in speech and reading Day 1 (pre-treatment)Immediately before the treatment (Day 1)Stuttering severity will be calculated on video recordings taken during speaking and reading tasks. Stuttering Severity Instrument - 4th Edition (SSI-4) scale will be used for this.
Severity of stuttering in speech and reading Day 1 (post-treatment)Immediately after the treatment (Day 1)Stuttering severity will be calculated on video recordings taken during speaking and reading tasks. Stuttering Severity Instrument - 4th Edition (SSI-4) scale will be used for this.
Severity of stuttering in speech and reading Day 2 (pre-treatment)Immediately before the treatment (Day 2)Stuttering severity will be calculated on video recordings taken during speaking and reading tasks. Stuttering Severity Instrument - 4th Edition (SSI-4) scale will be used for this.
Severity of stuttering in speech and reading Day 2 (post-treatment)Immediately after the treatment (Day 2)Stuttering severity will be calculated on video recordings taken during speaking and reading tasks. Stuttering Severity Instrument - 4th Edition (SSI-4) scale will be used for this.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026